Clinigen Group, a specialty global pharmaceutical company, has agreed to acquire Link Healthcare, a specialist pharmaceutical and medical technology business focused on the Asia, Africa and Australasia (AAA) region, for an initial consideration of $67.9 million and a maximum of approximately $152.5 million based on achievement of milestones.
Chief Executive Officer of Clinigen Peter George said, “This strategic acquisition is a key step in our ambitions to strengthen and broaden our international distribution network across the AAA region—Asia, Africa and Australasia. Link, which is located in the three key hubs of Singapore, South Africa and Australia, has excellent local knowledge and connections as well as established customers.
“There is a strong, and increasing, demand for hospital-based oncology, anti-infective, orphan and other crucial drugs in pharmerging markets. Link will enable us to directly supply much needed, but not always licensed, medicines into these growing markets.”